236 related articles for article (PubMed ID: 38203635)
21. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
[TBL] [Abstract][Full Text] [Related]
23. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
24. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression.
Tanaka M; Kunita A; Yamagishi M; Katoh H; Ishikawa S; Yamamoto H; Abe J; Arita J; Hasegawa K; Shibata T; Ushiku T
Liver Int; 2022 Oct; 42(10):2329-2340. PubMed ID: 35833881
[TBL] [Abstract][Full Text] [Related]
25. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.
Saborowski A; Saborowski M; Davare MA; Druker BJ; Klimstra DS; Lowe SW
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19513-8. PubMed ID: 24154728
[TBL] [Abstract][Full Text] [Related]
26. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
27. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review).
Yang R; Song Y; Shakoor K; Yi W; Peng C; Liu S
Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35302174
[TBL] [Abstract][Full Text] [Related]
28. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
29. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
[No Abstract] [Full Text] [Related]
30. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
[TBL] [Abstract][Full Text] [Related]
31. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience.
Wang L; Zhu H; Zhao Y; Pan Q; Mao A; Zhu W; Zhang N; Lin Z; Zhou J; Wang Y; Zhang Y; Wang M; Feng Y; He X; Xu W; Wang L
J Transl Med; 2020 Jul; 18(1):273. PubMed ID: 32631434
[TBL] [Abstract][Full Text] [Related]
33. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.
Wang XY; Zhu WW; Wang Z; Huang JB; Wang SH; Bai FM; Li TE; Zhu Y; Zhao J; Yang X; Lu L; Zhang JB; Jia HL; Dong QZ; Chen JH; Andersen JB; Ye D; Qin LX
Theranostics; 2022; 12(1):260-276. PubMed ID: 34987644
[No Abstract] [Full Text] [Related]
34. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.
Oishi N; Kumar MR; Roessler S; Ji J; Forgues M; Budhu A; Zhao X; Andersen JB; Ye QH; Jia HL; Qin LX; Yamashita T; Woo HG; Kim YJ; Kaneko S; Tang ZY; Thorgeirsson SS; Wang XW
Hepatology; 2012 Nov; 56(5):1792-803. PubMed ID: 22707408
[TBL] [Abstract][Full Text] [Related]
35. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
36. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.
Robertson S; Hyder O; Dodson R; Nayar SK; Poling J; Beierl K; Eshleman JR; Lin MT; Pawlik TM; Anders RA
Hum Pathol; 2013 Dec; 44(12):2768-73. PubMed ID: 24139215
[TBL] [Abstract][Full Text] [Related]
37. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
38. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma.
Younger NT; Wilson ML; Martinez Lyons A; Jarman EJ; Meynert AM; Grimes GR; Gournopanos K; Waddell SH; Tennant PA; Wilson DH; Guest RV; Wigmore SJ; Acosta JC; Kendall TJ; Taylor MS; Sproul D; Mill P; Boulter L
Cancer Res; 2022 Apr; 82(8):1548-1559. PubMed ID: 35074757
[TBL] [Abstract][Full Text] [Related]
39. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
[TBL] [Abstract][Full Text] [Related]
40. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
